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PURPOSE. Comparison of the parasympathetic and sympathetic neurons, including the
dopaminergic neural system, in dry eye (DE)–induced pathophysiology has not been
elucidated well. This study investigated the presence of dopamine receptors (DRs) and
their functional roles in the lacrimal glands (LGs) of DE-induced mice.
METHODS. After DE was induced in B6 mice for 2 weeks, the expression of tyrosine
hydroxylase (TH), dopamine, and DRs (DR1, DR2, etc.) in the LGs and corneas were
measured by quantitative RT-PCR, immunoblot, and ELISA. Using flow cytometry and
ELISA, immune cell infiltration and inflammatory cytokine expression were determined
in DE-induced LGs with or without DR blockers, SCH-23390 (DR1i), or melperone (DR2i).
Corneal erosion scores were also investigated.
RESULTS. The mRNA and protein levels of TH significantly increased in DE-induced LGs.
The dopamine concentration of LGs was 9.51 pmol in DE (versus naive: 1.39 pmol; P <
0.001). Both DR1 and DR2 mRNA expression were significantly enhanced in desiccating
stress compared with those in naive (3.7- and 2.1-fold, P < 0.001). Interestingly, DR1
and DR2 immunostaining patterns stained independently in DE-induced LGs. CD3+ and
CD19+ cell infiltration was significantly increased by DR2i (P < 0.001) but not by DR1i.
Furthermore, IFN-γ , IL-17, and TNF-α were significantly upregulated by DR2i compared
with the blow-only condition. The severity of corneal erosion and inflammation was also
aggravated by DR2i.
CONCLUSIONS. Upregulation of DR1 and DR2 was observed in DE-induced mouse LGs.
As the inflammatory conditions are aggravated by the inhibition of DRs, especially DR2,
their activity may be an important factor preserving ocular surface homeostasis.
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Neural integrity and reflex between the lacrimal gland(LG) and ocular surface are essential for ocular
surface homeostasis. Damage to the corneal nerves, arising
anywhere from cell bodies in the central nervous system
(CNS) to the nerve endings embedded in the corneal epithe-
lium, is thought to underlie several ocular surface diseases,
such as neurotrophic keratitis, neuropathic pain, and dry
eye (DE) disease.1,2 The neural network involved in the
neural regulation of tear production is extremely compli-
cated, both anatomically and functionally. The muscarine M3
receptor, nicotinic receptors, vasoactive intestinal peptide,3,4
substance P,5,6 and sympathetic system contribute to tear
production, in terms of regulating levels of aqueous fluid,
electrolytes, and soluble peptide production7,8; therefore,
the production of aqueous fluid and proteins is finely regu-
lated by many neuronal peptides and neurotransmitters in
addition to the cholinergic system.
Apart from the cholinergic system, the sympathetic and
dopaminergic systems play important roles in the exocrine
functions of the salivary glands9 and LGs.3,10,11 Dopamine
increases the salivary flow rate and protein secretion by
stimulating dopamine receptor 1 (DR1)–like receptors.12
Additionally, the secretion of amylase, the most abundant
protein in saliva, is mediated via specific DR1-like recep-
tors.13 Dopamine receptor 2 (DR2) has been found in a
wide variety of ocular tissues, such as in keratocytes,14 the
retinal pigment epithelium (RPE),15 and the corneal epithe-
lium.16 Within these tissues, DR2 has been reported to have
functional roles in preventing RPE cell death,15 reducing
intraocular pressure,17 and improving corneal wound heal-
ing and nerve density levels in a murine model.18 Unfortu-
nately, while there are a few previous studies reporting on
dopaminergic receptors within the ocular system, the data
on the influence of dopamine on the exocrine functions of
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ocular glands are sparse and often inconsistent.9 There have
been few studies on identifying the role of the dopaminergic
system in tear fluid secretion and dopamine subtype recep-
tor expression levels or patterns in LGs. Moreover, dopamine
has emerged as a fundamental regulator of inflammation,
and dysregulation of the dopaminergic system affects both
innate and adaptive immunity, contributing to the develop-
ment of autoimmune and inflammatory diseases.19
Hence, this study has three aims. The first is to deter-
mine the existence of dopaminergic receptor subtypes in
LGs and the ocular surface. The second is to determine the
expression levels and functional role of the dopaminergic
system in DE pathophysiology. The third is to investigate
the interaction and reciprocal between the parasympathetic
and dopaminergic systems in vivo using a DE murine model.
MATERIALS AND METHODS
Animals and DE Induction
Six- to 8-week-old male C57BL/6 mice (Charles River Labo-
ratory, Wilmington, MA, USA) were used according to the
standards outlined in the AVO Statement for the Use of
Animals in Ophthalmic and Vision Research. The research
protocol was approved by the Institutional Animal Care and
Use Committee of Yonsei University College of Medicine. DE
was induced by placing the mice in a controlled environ-
ment chamber (CEC). Mice in the CEC (with relative humid-
ity below 13% and 3-m/s flow rate) were subcutaneously
injected with 0.1 mL scopolamine hydrobromide (5 mg/mL;
Sigma-Aldrich, St. Louis, MO, USA) three times per day to
achieve maximum ocular surface dryness. Additionally, to
block the dopaminergic neurons, DR1 blocker (SCH-23390,
0.3 mg/kg; Cayman Chemical, Ann Arbor, MI, USA) and DR2
blocker (Melperone, 2 mg/kg; Tocris Bioscience, Abingdon,
UK) were injected subcutaneously, following a previously
published protocol.20–22 All data were retrieved from two
independent experiments (n = 5) in triplicate in each group.
Tissue Preparation
On each day of the experiment, mice were euthanized and
the corneas and LGs were collected. Each tissue sample was
halved and fixed in 3.7% paraformaldehyde for immunos-
taining or stored at –70°C for quantitative real-time poly-
merase chain reaction (qRT-PCR) or immunoblotting. The
detailed methods have been described in our previous stud-
ies.23,24
Tissue RNA Extraction and qRT-PCR
RNA was isolated from mouse LGs using an RNeasy Micro
Kit (QIAGEN, Valencia, CA, USA), and reverse transcription
was performed using a Superscript III Kit (Invitrogen, Carls-
bad, CA, USA). qRT-PCR was performed using SYBR Premix
Ex Taq (TaKaRa Bio, Inc., Otsu, Japan) with a StepOnePlus
Real-Time PCR System (Applied Biosystems, Foster City, CA,
USA). Preformulated primers for DRs and other targets are
described in the Table.
Immunofluorescent Staining
The method used for immunofluorescent (IF) staining has
been described previously.25 Briefly, the LGs and eyeballs
were harvested and cryopreserved by embedding in opti-
TABLE. List of Designed mRNA Primers Used for qRT-PCR
Gene Primer Sequence (5′→3′)
DR1 Forward GAG CAG GAC ATA CGC CAT TT
Reverse CCC TCT CCA AAG CTG AGA TG
DR2 Forward GAT GTG CAC AGC AAG CAT CT
Reverse AGG ACA GGA CCC AGA CAA TG
DR3 Forward CCC TCA GCA GTC TTC CTG TC
Reverse AAG AGA GGG TCC TGG CAT TT
DR4 Forward GTG TGT TGG ACG CCT TTC TT
Reverse CGC GTT GAA GAT GGT GTA GA
DR5 Forward CCA ATA CAA GCA GGG TGA G
Reverse AGG CAT GGG TAG CAT AGA
Tyrosine hydroxylase Forward CAG CTG GAG GAT GTG TCT CA
Reverse CAG CTG GAG GAT GTG TCT CA
mal cutting temperature compound before staining. The
histologic sections (5–7 μM) were collected on poly-L-
lysine-coated slides and blocked with rabbit, goat, or rat
serum followed by primary antibody conditioning for 40
minutes at room temperature and exposed to the follow-
ing primary antibodies: FITC-conjugated DR1 (rat mono-
clonal anti-mouse, 2 μg/mL; Abcam, Cambridge, UK), DR2
(rabbit polyclonal anti-mouse, 1 μg/mL; Abcam), and mouse
tyrosine hydroxylase (TH) (rat monoclonal anti-mouse, 2
μg/mL; ThermoFisher Scientific, Inc., Waltham, MA, USA).
Antibodies were diluted 1:100 to 1:200, and samples were
incubated overnight at 4°C in a dark room. After wash-
ing with Tris-buffered saline supplemented with Tween 20
(TBST), each section was exposed to secondary antibod-
ies for 1 hour. After another wash with TBST, the sections
were exposed to 4’,6-diamidino-2-phenylindole (PureBlu;
Bio-Rad, Hercules, CA, USA). Fluorescence microscopy
and/or confocal microscopy (Axio Imager 2; Carl Zeiss,
Oberkochen, Germany) were used to examine the samples.
Immunoblotting
Total protein concentrations of supernatant fractions were
determined using a bicinchoninic acid protein assay (Bio-
Rad). Equal amounts of protein aliquots were boiled in equal
volumes of 2 × SDS Laemmli sample buffer and resolved on
8% or 10% (w/v) with the following primary antibodies: anti-
TH (0.2 μg/mL; R&D Systems, Minneapolis, MN, USA) and
anti–β-actin (2 μg/mL; Abcam).
ELISA
Commercialized ELISA was performed to measure the
concentration of cytokines. Similarly, to measure the concen-
tration of dopamine, a specific ELISA kit (Abnova, Taipei,
Taiwan) was used. In addition, IFN-γ , IL-17, TNF-α (R&D
Systems, Minneapolis, MN, USA), and IL-8 (ThermoFisher
Scientific) levels were measured 14 days after DE induction,
with or without DR blockers, in LGs. All experiments were
repeated three times in at least triplicate.
Flow Cytometry
The flow cytometry strategy for LG cultures has been
described previously.25,26 Briefly, single-cell suspensions of
four LGs from each condition were prepared by treating
minced tissue fragments with 100 U/mL collagenase D
and 15 μg/mL DNase (Sigma-Aldrich) for 40 minutes at
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FIGURE 1. Expression of TH and dopamine in the LG and cornea in DE. (A) qRT-PCR analysis of TH mRNA expression levels in LGs and the
cornea 14 days after air blowing only or scopolamine (Sco) injection (n = 5, one-way ANOVA and Bonferroni-corrected Dunnett test for post
hoc analysis). *P< 0.05. **P< 0.01. ***P< 0.001. NS, not significant. (B,C) Representative immunoblotting assay (B) and immunofluorescence
staining (C) for TH (white arrows: green) in DE-induced LGs. Autofluoresceins were marked with brown (yellow arrows). Bar: 50 μM. All
data were retrieved from two independent experiments in triplicate in each group (n = 5, Mann–Whitney U test). *P < 0.05. **P < 0.01.
***P < 0.001. NS, not significant. (D) Using enzyme-linked immunosorbent assay, the concentration of dopamine was measured in LGs
7 days after DE induction (n = 5, Mann–Whitney U test). ***P < 0.001.
37°C. After blocking with 1 μg unlabeled anti-FcrR antibody
(clone 2.4G2), cells (1 × 106) were washed with RPMI 1640
and surface-stained with PE-Cy5–conjugated anti-CD3, FITC-
conjugated anti-CD4, and PE-conjugated anti-CD8 (eBio-
science, San Diego, CA, USA), and the cells were analyzed
using flow cytometry and fluorescence-activated cell sort-
ing (FACS) (FACS Calibur; Becton-Dickinson, Mountain View,
CA, USA).
Statistical Analysis
Continuous variables were examined for normality using
the Kolmogorov–Smirnov test. Variables that conformed to
normal distribution were presented as mean ± SD, and
those that were not normally distributed were presented as
median ± interquartile range. For two-sample analyses, the
Mann–Whitney U test was used. The Kruskal–Wallis test was
used to compare three or more groups. Bonferroni-corrected
Dunnett procedure, as a post hoc analysis, was also used to
compare each treated group and the control group. Statisti-
cal analysis was performed using SAS software (version 9.13;
SAS Institute, Cary, NC, USA) and R (version 3.2.5; Statistics
and Mathematics, Vienna, Austria). P < 0.05 was considered
significant.
RESULTS
Expression of TH and Dopamine in DE-Induced
LGs and Cornea
First, the mRNA expression of the dopamine induction
enzyme TH was measured in the LGs and cornea after DE
induction. Interestingly, TH level significantly increased in
LGs after DE induction by blowing air and increased even
more on combining blowing air with the administration of
scopolamine (Fig. 1A). However, TH expression was the
same with or without scopolamine injection with air-blowing
stimulus in the cornea. To determine the protein level of
TH in LGs, immunoblotting for TH was performed, and
upregulation of TH in the air-blowing condition was found
compared to the naive status (Fig. 1B). However, we did
not find a TH protein-level difference between scopolamine
injection and blow-only conditions despite the difference in
mRNA levels. Confocal microscopy showed that TH was only
present along the nerve leashes located between the acinar
cells or excretory ducts (Fig. 1C), which is in accordance
with the results of a previous study.10
Then, we measured the concentration of dopamine in
the LGs that was significantly elevated from 7 days after DE
induction and continued until 14 days. There was no differ-
ence in the level of dopamine between days 7 (Fig. 1D) and
14 after DE induction (data not shown).
Enhanced Dopamine Receptor Expression in
DE-Induced LGs
Although the expression of DR1 in the corneal epithe-
lium has been previously reported in humans,27 mice,28 and
rabbits,29 there have been few reports on the dopaminergic
receptor system in the LGs. Therefore, we measured the level
of DRs using qRT-PCR in LGs as well as the cornea. Inter-
estingly, expression of the subtypes of these receptors was
quite different. In LGs, DR1 and DR2 expression was signif-
icantly upregulated under air-blowing conditions. In the
cornea, DR1 significantly increased under air-blowing condi-
tions (Fig. 2A); however, DR2 mRNA was significantly down-
regulated by air blowing. When the locomotive expression
of DR1 and DR2 was compared, DR2 expression was found
to be much higher in LGs than in the cornea. However, DR1
expression was dominant in the cornea compared to that in
LGs. DR3 and DR4 expression did not change after DE induc-
tion in the cornea; however, a slight upregulation of DR3
expression was found in LGs (P= 0.033). DR5 mRNA expres-
sion was not enhanced in LGs under air-blowing conditions,
despite the upregulation of DR1 expression (Fig. 2A).
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FIGURE 2. Expression of DR subtypes in DE-induced LGs. (A) qRT-PCR analysis of DR subtype mRNA expression levels in the cornea and
LGs 14 days after air blowing. (B) Representative confocal microscopic findings for DR1 and DR2 (white arrows) immunostaining in LGs
after 14 days of DE induction (n = 5, Mann–Whitney U test). *P < 0.05. **P < 0.01. ***P < 0.001. NS, not significant. Bar: 50 μM.
FIGURE 3. Determining leukocyte infiltrations in DE-induced lacrimal glands by neutralizing dopaminergic receptors DR1/DR2. Flow cytom-
etry of CD3-, CD4-, and CD19-expressing cells 14 days after DE induction in LGs with or without DR1 (DR1i: SCH-23390, 0.3 mg/kg) or
DR2 inhibitor (DR2i: melperone, 2 mg/kg) treatment (n = 5, one-way ANOVA and Bonferroni-corrected Dunnett test for post hoc analysis).
*P < 0.05. **P < 0.01. ***P < 0.001. N, naive condition.
With confocal microscopy examination of the receptor
expression in LGs, we found that the expression pattern
did not overlap between DR1 and DR2. Both receptors were
expressed in different acinar cells. Under normal conditions,
the receptors were not found in the LG acinar cells. However,
with DE induction, the receptors were highly expressed
in some acinar and tubular epithelial cells of the LGs
(Fig. 2B).
Increased Leukocyte Infiltration in LGs by
Neutralizing Dopaminergic Receptors DR1/DR2
The expression of LG inflammatory cytokines and number
of cells were investigated under receptor neutralizing condi-
tions to determine the functional role of DR subtypes in DE.
T- and B-cell levels were significantly increased in LGs after
DE induction, as we reported previously.23–25 Surprisingly,
dopaminergic receptor blockade significantly increased the
percentage of infiltrating cells. Furthermore, all levels of
three cell types that were investigated (CD3+, CD4+, and
CD19+) were significantly increased only via the inhibition
of DR2 and not that of DR1 (Fig. 3). The mean percentage
of CD3+ and CD4+ cells in DE increased by 2.4- and 1.9-
fold after DR2 blocking, respectively. For CD19+ cells, the
cell percentage was increased by 3.2-fold in DE with DR2
inhibition (DR2i).
Next, we measured the levels of several DE-related
key cytokines, such as IFN-γ , IL-17, IL-8, and TNF-α. All
cytokines were significantly elevated after DE induction,
which was accelerated by DR2i (Fig. 4). The expression of
IFN-γ was similar between DR1 inhibition (DR1i) and air
blowing conditions. However, IFN-γ expression was signif-
icantly upregulated after DR2i. Similar to IFN-γ , IL-17 and
IL-8 levels were significantly higher only after DR2i under
air-blowing conditions (Fig. 4). However, TNF-α expres-
sion after DR2i was similar to that after DR1i, despite the
increased expression by air blowing. Besides the level of IL-
17 (P < 0.001), when both receptors were inhibited simulta-
neously, no cytokine expression levels were synergistically
upregulated, and these were similar to those observed after
DR2i.
Enhanced Ocular Surface Inflammatory
Conditions by Neutralizing Dopaminergic
Receptor DR2
From the above results, we found that DRs had a role in
the downregulation of the inflammatory status of LGs. Next,
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FIGURE 4. Measurement of inflammatory cytokine levels in DE-induced LGs using ELISA. IFN-γ , IL-17, IL-8, and TNF-α expression levels
in LGs were measured 14 days after DE induction with or without dopamine receptor inhibitors. BRi, both receptors inhibited; DR1i, SCH-
23390; DR2i, melperone; N, naive condition. All experiments were repeated three times in at least triplicate (n = 5, one-way ANOVA and
Bonferroni-corrected Dunnett test for post hoc analysis). *P < 0.05. **P < 0.01. ***P < 0.001. NS, not significant.
FIGURE 5. Ocular surface inflammatory conditions via dopaminergic receptor blocker treatment. (A, B) Mean corneal erosion scores
(A) and representative corneal photo (B) of each treatment group 14 days after DE induction. (C) qRT-PCR analysis of each cytokine
in the DE-induced corneas. BRi, both receptors inhibited; DR1i, DR1 blocker (SCH-23390); DR2i, DR2 blocker (melperone); N, naive condi-
tion; Sco, scopolamine injection. All experiments were repeated three times and analyzed in at least triplicate (n = 5, one-way ANOVA and
Bonferroni-corrected Dunnett test for post hoc analysis). *P < 0.05. **P < 0.01. NS, not significant.
the inflammatory status of the ocular surface was evalu-
ated by neutralizing the dopaminergic system. Surprisingly,
the corneal erosion score was significantly increased after
DR2i treatment for DE, similar to that of the scopolamine-
treated condition (Figs. 5A, 5B). However, after DR1i treat-
ment, it was similar to that under air-blowing-only condi-
tions in DE. Next, the ocular surface cytokine levels were
measured using qRT-PCR. As observed in LGs, IFN-γ and
IL-17 levels were significantly elevated under air-blowing
conditions and after DR2i. However, DR1i did not signif-
icantly increase the expression of inflammatory cytokines
(Fig. 5C). Interestingly, the expression of IFN-γ and IL-17A
was comparable between scopolamine- and DR2i-treated
mice.
DISCUSSION
In this in vivo study, both the mRNA and protein levels of
TH were found to be upregulated in DE-induced LGs. Addi-
tionally, the dopamine concentration and DR2 expression
in LGs were significantly upregulated. Systemic blocking
of DR2 enhanced lymphocyte infiltration and upregulated
cytokine expression in LGs, subsequently aggravating the
ocular surface inflammatory conditions in DE disease. There-
fore, not only the cholinergic system but also the dopaminer-
gic receptor, especially DR2, may regulate the inflammatory
status of LGs in DE disease.
Dopamine was first identified in human tears several
decades ago.30 In addition, the enzymes involved in
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dopamine metabolism (e.g., TH and dopamine-β-
hydroxylase) have been found in LGs and the ocular
adnexa of mice,31,32 rats,11 rabbits,33 monkeys,34,35 and
humans.8 However, there are sparse data available regard-
ing the pathophysiologic role of the dopaminergic system in
DE disease. Moreover, most previous studies have focused
on the sympathetic or other monoamine neural systems
(e.g., substance P) to determine the anatomic location
and functional role in the ocular system and DE disease.
However, dopamine is not only a tyrosine metabolite, key to
producing adrenaline, but also an active neurotransmitter,
thus playing a significant role in several neurodegenerative
diseases. Therefore, we investigated the role of dopamine
in DE disease pathophysiology by focusing on the LGs.
As in Parkinson disease, a neurodegenerative disease of
the CNS, DE disease also has a neuroinflammatory compo-
nent explained by the dysfunctional neural regulation and
enhanced inflammatory conditions on the ocular surface
with aging. As TH activity is the “rate-limiting step” for
dopamine and norepinephrine production, we first deter-
mined TH expression in LGs through mRNA expression
levels, immunoblotting, and IF staining. Interestingly, TH
mRNA expression was gradually enhanced under both air-
blowing and scopolamine injection conditions. However,
at the protein level, we could not determine the differ-
ence between air blowing and scopolamine injection despite
the upregulation of TH compared to the naive condition.
These results may indicate that the air-blowing stress is suffi-
cient for maximum TH induction. Furthermore, choliner-
gic blocking by scopolamine did not affect TH expression
(Figs. 1A, 1B), which indicated that there was no reciprocal
or interfering neural regulation between the cholinergic and
dopaminergic systems under the DE disease-mimicking air-
blowing condition. As mentioned above, to find a common
pathway for the neural regulation between neurodegenera-
tive diseases and DE disease, we expected a reciprocal regu-
lation between the cholinergic and dopaminergic systems
in DE disease. However, at least in the murine model, TH
expression levels were independently regulated and not
affected by the muscarinic receptor blocker scopolamine.
Another interesting finding in the dopaminergic system in
DE was dopaminergic receptor subtype expression. Under
basal, non-DE stress conditions, DR1 and DR2 expression
were not observed with confocal microscopy. However,
after DE induction, the mRNA levels of both receptors
were enhanced in the LGs (Fig. 2A). Interestingly, confo-
cal microscopy revealed that DR1 was mainly expressed in
the secretory ducts and the portal area; however, DR2 was
mainly located in the acinar cells. Additionally, DR1 mRNA
expression levels were much higher in the cornea than in
the LGs and increased both on the ocular surface and in
the LGs synchronously in response to DE stress. In contrast,
DR2 expression was much higher in LGs than in the cornea
and was upregulated only in LGs (Figs. 2A, 2B). Although
further detailed studies are needed, these results imply that
the upregulation of DR2 is more sensitive and responsible
for neural regulation in DE-stressed LGs. In addition, consid-
ering the localization pattern of DR1 and DR2 in LGs, the
latter located in the acinar, DR2 might have a more direct
role in aqueous tear and protein production.
To determine the functional role of DR subtypes, we
used melperone and SCH-23390 to block DR2 and DR1,
respectively. The functional roles of DR1 and DR2 recep-
tors are usually contradictory, and DR1 and DR5 are DR1-
like subtypes, while the DR2-like subtypes include DR2,
DR3, and DR4.36,37 Therefore, the effect of SCH-23390
might mimic the DR1-like subtype blocking effect. Similarly,
melperone might block all DR2-like subtype receptors as
well as histamine receptors (e.g., 5-HA2A).38,39 As a result
of a simple neural blocking in vivo study, DR2i showed a
significant elevation of inflammatory cytokine expression
and cell numbers. Although the levels of IL-17A, TNF-α,
and IL-8 were significantly elevated compared with those
of IFN-γ , dopaminergic and cholinergic systems might not
be responsible for Th1 or Th17 responses, respectively, and
could have specific functional roles in enhancing the inflam-
matory response. Nonetheless, these systems may regulate
DE-induced inflammatory responses through their receptor-
specific systems. This might be plausible, especially when
previous studies have shown enhanced IFN-γ and IL-17
expression using a muscarinic blocking agent with or with-
out air-blowing stress.40
The dopaminergic neurons regulate not only the LG
inflammatory status but also ocular surface inflammation.
After blocking DR1 or DR2, the erosion score was signif-
icantly elevated (Figs. 5A, 5B), although DR2 blocking
increased the scores more significantly. Interestingly, the
erosion score and inflammatory cytokine expression levels
were not different between the scopolamine and DR2i
groups. These results might indicate a close interaction
between cholinergic and dopaminergic systems, suggest-
ing a “common” and not an “independent” or “synergistic”
neural regulation in DE disease pathophysiology. However,
we did not identify a synergy between cholinergic and
dopaminergic systems (data not shown) in the DE disease
inflammatory response in either the LGs or the cornea. In
addition, considering the topographic patterns and different
levels of inflammation between DR1 and DR2 in the LGs
(Fig. 2B), both receptors might be independently involved
in DE-induced inflammatory responses.
This study has several limitations. For identifying the
source of dopamine secretion, we relied on the staining
pattern and concluded that TH only existed on the neural
leashes in the LGs. However, TH is found in many types
of inflammatory cells, especially T and dendritic cells.41,42
Considering inflammatory T and myeloid cell infiltration in
DE disease, the source of dopamine might be more diverse
and complicated in DE-induced LGs. Moreover, we did not
investigate dopamine metabolism by measuring levels of
dopamine β-hydroxylase that converts dopamine to nore-
pinephrine. Although the sympathetic system is an essen-
tial system for tear production,10,31 we focused on dopamine
induction and receptor expression in LGs in this study. The
activity of dopamine β-hydroxylase and the sympathetic
system should be investigated in a collaborative manner
with the dopaminergic and cholinergic systems. Last, human
dopaminergic receptors might be expressed differently from
those of mice, whether in healthy or diseased states. Thus, a
study using human LG samples is needed in the future and
is essential to understand the specific neural regulation of
DE disease.
In conclusion, we found that the dopaminergic neural
system played a significant role in DE pathophysiology, simi-
lar to the cholinergic system. However, the neural regula-
tion between both systems appears to be extremely compli-
cated and does not involve collaborative work as a recipro-
cal role in DE disease. Further in vitro studies with human
samples may provide more precise data for the role of the
dopaminergic neural system in LG inflammation and the
collaborative role of DRs with muscarinic receptors and thus
Dopaminergic Neural System in DE IOVS | April 2021 | Vol. 62 | No. 4 | Article 14 | 7
reveal a target to treat dysfunctional neural regulation in DE
disease.
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